United Health Products, Inc.: insider trades · United States · SEC (Form 4)

About United Health Products, Inc.

United Health Products, Inc. (ticker UEEC) is a U.S.-based micro-cap medical technology company and, at this stage, it is quoted on the OTCQB market in the United States rather than on NYSE/NASDAQ. For French-speaking investors, the company represents a highly specialized healthcare/medtech case focused on hemostatic wound-care products. Its core asset is CelluSTAT™, an absorbable hemostatic gauze made from natural cellulose and designed to help control mild to moderate bleeding. The company describes CelluSTAT as a sterile, biocompatible product that is cut, packaged, and sterilized in the United States with FDA-registered partners. In practical terms, UEEC is a development-stage company built around a single technology platform and a narrow clinical use case. From a business standpoint, United Health Products is trying to solve a universal medical need: bleeding control. Its target end markets include surgery, dialysis, dentistry, and emergency medicine. However, the strategic center of gravity remains the company’s effort to obtain FDA PMA approval for a Class III indication that would support use of CelluSTAT in internal surgical bleeding. That makes the investment case primarily regulatory and clinical rather than commercial. Until broader approval is secured, the business remains pre-scale, with limited or no recurring operating revenue and a heavy reliance on external vendors, consultants, and financing. Historically, the company has been organized as a lean U.S. issuer incorporated in Nevada, while recent filings and corporate materials show operational addresses in New Jersey and a small footprint overall. Leadership is also tightly held: Brian Thom has served as CEO since December 2020, and the company highlights a compact management structure. That profile is consistent with a small development-stage medtech company rather than a mature medical device manufacturer. Recent developments have been driven by FDA progress, capital structure, and filing activity. The latest annual and quarterly disclosures indicate that the company remains loss-making, without meaningful revenue, and continues to disclose going-concern risk. At the same time, management has reported ongoing engagement with the FDA, including steps related to a new pivotal IDE study and a substitute sponsor arrangement approved by the agency. The company also drew attention from market participants tracking SEC Form 4 insider transactions, which can be relevant in a micro-cap context but should be interpreted cautiously given the company’s dependence on regulatory milestones and external funding. For investors in France, Belgium, and Switzerland, UEEC should therefore be viewed as a speculative U.S. healthcare story with binary elements: if regulatory execution improves, the addressable opportunity may expand; if not, the company may need to revisit its commercialization path. The central investment thesis remains tied to FDA approval, funding capacity, and the company’s ability to move CelluSTAT from development into broader clinical adoption in the United States.